Chest ACCP Education Calendar
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text Free
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stoller, J. K.
Right arrow Articles by Walsh, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stoller, J. K.
Right arrow Articles by Walsh, J.
(Chest. 2000;118:843-848.)
© 2000 American College of Chest Physicians

Formation and Current Results of a Patient-Organized Registry for {alpha}1-Antitrypsin Deficiency*

James K. Stoller, MD, FCCP; Mark Brantly, MD; Lora E. Fleming, MD, PhD, MPH, MSc; Judy A. Bean, PhD and John Walsh for the Alpha One Foundation Research Network Registry Investigators{dagger}

{dagger} A complete list of investigators is located in the Appendix.

Correspondence to: James K. Stoller, MD, FCCP, Department of Pulmonary and Critical Care Medicine, A 90, The Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; e-mail: stollej{at}ccf.org

Background: Significant challenges exist to investigating uncommon illnesses because too few patients are seen at any single clinical center to permit appropriate research studies. Recognizing this impediment to clinical research in {alpha}1-antitrypsin deficiency, the Alpha One Foundation, a patient-organized research foundation, has collaborated with clinician-scientists to organize a voluntary registry of individuals with {alpha}1-antitrypsin deficiency.

Purpose: To facilitate clinical research in {alpha}1-antitrypsin deficiency by organizing a registry of affected individuals willing to be approached to participate in clinical studies.

Methods: Elements of the Alpha One Foundation Research Network Registry include a Medical and Scientific Advisory Committee, composed of physician-investigators and patient advocates, designated clinical resource centers at medical institutions with expertise in the management of individuals with {alpha}1-antitrypsin deficiency, and a data coordinating center with responsibility for database management and analysis. Questionnaires requesting information about demographic features, {alpha}1-antitrypsin phenotype, smoking history, and health-care utilization were distributed to prospective registrants through the following channels: mailings from the Alpha One Foundation; mailings from the clinical resource centers; and distribution by home-care and pharmaceutical companies. Information from this questionnaire formed the basis of the initial registry database.

Results: Between May 1997 and June 1999, 7,789 forms were distributed, and forms were returned by 712 unique registrants. Registrants have the following characteristics: mean (± SD) age, 49.3 ± 13.2 years; women, 47.7%; white, 96.2%; PI*ZZ phenotype, 70.7%; ex-smokers, 73.3%; COPD patients, 87.2% (emphysema patients, 54.2%; chronic bronchitis patients, 33%); and self-reported liver disease, 6.4%. The mean number of physician visits reported by registrants in the preceding 12 months was 7.8 ± 9.4, 59% reported currently receiving IV augmentation therapy, and 35% reported using supplemental oxygen at home. Examples of ongoing research studies using this unique database include: (1) a case-control study to evaluate occupational risk factors for obstructive lung disease in individuals with {alpha}1-antitrypsin deficiency and (2) a study to evaluate the health-care costs for affected individuals.

Conclusions: A registry currently including 712 individuals with {alpha}1-antitrypsin deficiency has been organized through a collaboration between physician-investigators and a patient-organized research foundation. Use of the registry has already facilitated studies that were previously difficult because of the paucity of identifiable study subjects. The registry cohort promises to provide an important resource for future clinical and epidemiologic studies.

Key Words: {alpha}1-antitrypsin deficiency • emphysema • patient-organized • registry




This article has been cited by other articles:


Home page
 ChestHome page
M. A. Campos, A. Wanner, G. Zhang, and R. A. Sandhaus
Trends in the Diagnosis of Symptomatic Patients With {alpha}1-Antitrypsin Deficiency Between 1968 and 2003
Chest, September 1, 2005; 128(3): 1179 - 1186.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
I Ferrarotti, J Baccheschi, M Zorzetto, C Tinelli, L Corda, B Balbi, I Campo, E Pozzi, G Faa, P Coni, et al.
Prevalence and phenotype of subjects carrying rare variants in the Italian registry for alpha1-antitrypsin deficiency
J. Med. Genet., March 1, 2005; 42(3): 282 - 287.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
T. R. Gildea, K. M. Shermock, M. E. Singer, and J. K. Stoller
Cost-Effectiveness Analysis of Augmentation Therapy for Severe {alpha}1-Antitrypsin Deficiency
Am. J. Respir. Crit. Care Med., May 15, 2003; 167(10): 1387 - 1392.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Chest Physicians.